A unique set of skin microbiota for each individual

The fourth most populated microbial niche in the human body,2 the skin is home to a complex community of microorganisms.2 Bacteria, fungi, parasites and viruses live together on the skin in a unique balance specific to each individual, to the point where some investigators speak of an individual microbial fingerprint.5

The skin microbiota Atopic dermatitis: nasal and skin microbiomes associated with disease severity Role of the microbiota in gut-brain communication Antibiotic exposure during first six years of life disrupts gut microbiota and impairs child growth

Staphylococcus epidermidis

Each individual is not characterized by one but by multiple skin microbiota. In fact, the skin microbiota varies “horizontally”, according to skin area (face, armpits, etc.), but also “vertically”, according to the layers that make up the skin epithelium.

BACTERIA, FUNGI, VIRUSES AND PARASITES

Although easily accessible, the skin microbiota remains poorly understood. Its density is believed to be low compared to that of the large intestine, instead resembling that of the small intestine, i.e. around 1011 bacteria.1 It is the fourth largest microbial niche in the body in terms of the number of microorganisms, just after the digestive tract, the oral cavity and the vagina.2

It hosts several bacterial phyla (Actinobacteria, Firmicutes, Proteobacteria and Bacteroidetes), archaea, and fungal species mainly from the genus Malassezia.2,3 Among the bacterial species identified are included Cutibacterium acnes and Staphylococcus epidermidis, although the strains present differ depending on the individual, the state of their skin (healthy or otherwise) and the sampling site.3,6

Lastly, although not well described,2 numerous viruses (papillomavirus, adenovirus, etc.) have been identified on the skin of healthy individuals, as well as phages that target C. acnes and S. epidermidis, suggesting the existence of a complex virome. Parasites (such as Demodex mites, etc.), few in number, are even more scantly described.3

“HORIZONTAL” VARIATION ACCORDING TO SKIN AREA

The skin is not a homogeneous habitat. The surface of the skin is acidic, salty and aerobic, whereas the invaginations of the hair follicles offer a lipid-rich and anaerobic environment6.

Three major niches are generally identified based on properties such as pH, temperature, humidity, perspiration levels and lipid content:1,3,4

  • sebaceous areas (face, chest, back) that secrete lipid-rich sebum;
  • dry areas (forearms, palm of the hand);
  • humid areas (armpits, elbow crease, nostril, back of the knee and groin), where numerous sweat glands participate in thermoregulation (sweat), acidify the skin and secrete antibacterial peptides.

Some authors distinguish a fourth area in the foot (nails, heel and space between toes)4 (see table).

These areas are separate ecological niches, each with a unique microbial community: the most exposed and dry areas, such as the hands, are the most diverse; the armpit, which is moist and rich in sweat, is dominated by Corynebacterium and Staphylococcus species; while lipid-rich areas, such as the face, display much less diversity (Cutibacterium bacteria, fungi of the genus Malassezia, and Demodex folliculorum mites).3

Microbiota also vary in density from one skin area to another: from 102 bacteria per cm2 on the fingertips or back, to 106 bacteria per cm2 on the forehead or in the armpits.2

Image

“VERTICAL” VARIATION ACCORDING TO SKIN LAYER

For a long time, it was thought that microbial life in the skin was limited to the epidermis, hair follicles, and sebaceous and sweat glands. However, microorganisms also seem to live in the deeper layers of the skin, i.e., the dermis and the underlying adipose tissue.2

On the skin’s surface, the deeper into the stratum corneum the fewer microorganisms are present.1

Then, from the surface to the subcutaneous regions, the microbiota changes and gradually loses its individual characteristics.4,5

In the dermis and subcutaneous adipose tissues, there seems to be more Proteobacteria while there are less Actinobacteria and Firmicutes than in the epidermis.2

Summary
Off
Sidebar
Off
Migrated content
Activé
Updated content
Désactivé
Old content type
pro_dossiers_article
Hide image
Off
Dossier detail

Using recombinant endolysins to treat bacterial vaginosis

A study has shown that by using recombinant endolysins encoded on a prophage it is possible to eliminate the bacterial biofilm responsible for bacterial vaginosis without damaging the beneficial bacteria of the vaginal microbiota. These are promising results.

The vaginal microbiota Vaginal microbiota: a marker for papillomavirus progression? The role of the vaginal, uterine and gut microbiota in endometriosis

35% Only 1 in 3 women know that bacterial vaginosis is associated with an imbalance in the vaginal microbiota

Bacterial vaginosis is a quite common disorder in women of reproductive age, with a prevalence estimated at 10%–30% worldwide. It is associated with an increased risk of infertility and complications during pregnancy. It is also a risk factor for contracting sexually transmitted diseases. The condition is characterized by an imbalance of the vaginal microbiota and a biofilm formed on the vaginal epithelium, which is initiated and dominated by Gardnerella bacteria. This biofilm is frequently refractory to antibiotic treatment. Antibiotics are effective in quickly reducing symptoms but are associated with a recurrence rate of up to 60% within six months of treatment. A new study has investigated (sidenote: Endolysins Bacteriophage enzymes that lyse the bacterial wall, allowing the release of phages. )  of the type 1,4-beta-N-acetylmuramidase encoded on Gardnerella (sidenote: Prophages Bacteriophage genomes integrated into the host genome. (Saussereau and Debarbieux 2012) )  as an alternative treatment.

Bactericidal effect 10 times higher than wild type

To this end, the authors generated several engineered endolysins via domain shuffling. They compared their bactericidal activity on Gardnerella strains to that of wild-type endolysins. The bactericidal activity of the recombinant endolysins was 10 times that of any wild-type enzyme. When tested against a panel of 20 Gardnerella strains (from (sidenote: G. vaginalis, G. leopoldii, G. piotii and G. swidsinskii ) ), the most active endolysin, called PM-477, showed superior efficacy compared to the antibiotics tested (metronidazole, tinidazole, clindamycin). Furthermore, PM-477 had no effect on beneficial lactobacilli or other species of vaginal bacteria. According to the authors, PM-477 is highly selective for Gardnerella and kills strains of each of the four main species without affecting beneficial lactobacilli or other species typical of the vaginal microbiota. The effect of PM-477 was confirmed by microscopy in mixed cultures of Gardnerella and lactobacilli. PM-477 (at 460 µg/mL for 5 h) lysed G. vaginalis and G. swidsinskii cells in monoculture, but also selectively lysed them in mixed cultures alongside lactobacilli without affecting the latter.

Efficacy in patient samples

To go further and analyze the efficacy of PM-477 in a physiological environment closely resembling the in vivo situation, the researchers treated vaginal swabs from 15 bacterial vaginosis patients and analyzed them by fluorescence in situ hybridization (FISH). They showed that in 13 of the 15 cases, PM-477 eradicated the Gardnerella bacterium and physically dissolved the biofilms without affecting the vaginal microbiota. For the authors, endolysins are a promising therapeutic alternative to antibiotics for the treatment of bacterial vaginosis. This is a significant finding since antibiotics are frequently a cause of recurrence and resistance in the treatment of the disease.

Summary
Off
Sidebar
On
Migrated content
Activé
Updated content
Désactivé
Old content type
pro_article
Hide image
Off
News

Autism: when the gut calls the shots

The gut is often referred to as our second brain. For good reason, since it seems to be intimately linked to the ‘first’ brain. The quality of the gut microbiota is a gauge of our morale, our behavior and even our mental health, and may also influence the severity of symptoms in neurobiological diseases such as autism.

The gut microbiota Autism-spectrum disorders
Actu GP : Autisme : quand l’intestin fait la pluie et le beau temps

What causes Autism Spectrum Disorders (ASD)? The question has puzzled the scientific community for decades. While the gut cannot fully explain the causes of ASD (characterized by difficulties in socializing and communicating, or even obsessive-compulsive disorders (OCD)), it may provide some of the answers. These answers are to be found in the billions of bacteria and other microorganisms that populate the gut microbiota, for better or worse.

Gut disorders and ASD: a dangerous liaison

Since ASD was first described in 1943, numerous symptoms have been identified. Gut disorders (diarrhea, constipation, irritable bowel, etc.) are among the most standard physical symptoms. Children with ASD experience three to four times more gastrointestinal disturbances than the norm. Severe autism often goes hand in hand with the most severe gut disorders–and vice versa. In fact, researchers have even shown that autistic patients show an improvement in behavior following treatment of a gastrointestinal disorder. They therefore became interested in the mechanisms behind these gastrointestinal disorders and took a closer look at the gut microbiota.

A microbiota that believes itself to be the brain

Observation no. 1: autistic patients often present an altered gut flora (dysbiosis) that is poor in beneficial bacteria and richer in microbes involved in certain gut disorders (diarrhea, constipation, etc.). Not content with troubling the gut, these microbes also produce “signal” molecules used by the gut and the brain to communicate. Produced to excess, these molecules could interfere with the communication process and lead to behavioral disorders such as those encountered in ASD.

A leaky gut?

Observation no. 2: the gut barrier no longer does its job, i.e., preventing microbes, allergens and other foreign molecules from entering the bloodstream. The immune system is activated as a result, triggering inflammatory reactions. Many autistic patients exhibit gut permeability, gut and neuronal inflammation and gut disorders associated with a response to heightened stress. These data suggest a strong gut-brain link in ASD. However, the mechanisms by which gastrointestinal disorders contribute to autism are extremely complex. Further research is therefore required to identify therapies to treat these gut problems and improve the quality of life of patients with ASD.

Summary
Off
Sidebar
Off
Migrated content
Activé
Updated content
Désactivé
Old sources

Sources:

Bjørklund G, Pivina L, Dadar M, et al. Gastrointestinal alterations in autism spectrum disorder: What do we know? Neurosci Biobehav Rev. 2020 Nov;118:111-120. doi: 10.1016/j.neubiorev.2020.06.033. Epub 2020 Jul 1.

Old content type
article
Hide image
Off
News

Oral microbiota, a risk factor for lung cancer?

A first prospective study conducted in never-smokers suggests a link between diversity in oral microbiota and the risk of developing lung cancer. This new insight remains to be confirmed.

The ENT microbiota Can the lung microbiota reliably predict lung transplant rejection? Lung microbiota: a prognostic marker of COPD? Gut microbiota is involved in lung cancer

Lung cancer is the leading cause of death by cancer worldwide. While active tobacco use is the main risk factor, 25% of cases occur in non-smokers, a high percentage not fully explained by the major risks identified (passive smoking, pollution, family history, etc.). In addition to the gut microbiota, which is involved in the development of certain gastrointestinal cancers, other microbial ecosystems have also been associated with cancer risk. In this study, the authors investigated whether the oral microbiota’s composition and its ability to colonize the respiratory tract are involved in the development of lung cancer.

Depleted microbiota, increased risk

Their prospective study involved the long-term follow-up of more than 136,000 never-smoker Shanghai residents (61,500 men, 75,000 women), with follow-up visits every 2-3 years. A saliva sample taken at the outset was analyzed in all subjects reporting lung cancer and in an identical number of controls, matched for sex, age, date and time of sample collection, previous antibiotic treatment, etc. Metagenomic shotgun sequencing was then used to compare the 114 subjects diagnosed with lung cancer with the same number of controls. This analysis found a greater risk of developing lung cancer where the oral microbiota lacks bacterial diversity.

Greater abundance of Firmicutes is harmful

The inherent composition of the oral microbiome also appears to play a major role. Among the population studied, an increase in the relative abundance of Spirochaetes and/or Bacteroidetes was associated with a lower risk of lung cancer. Conversely, a greater abundance of bacteria belonging to the Firmicutes phylum, particularly Lactobacillales, was associated with an increased risk of lung cancer. The authors point out that these results coincide with those of previous studies showing a link between Firmicutes and certain respiratory diseases (chronic obstructive pulmonary disease or COPD, squamous cell carcinoma of the head and neck, and lung cancer).

ENT microbiota: further research required to clarify its field of action

This large-scale characterization of the oral microbiota sheds new light on the causes of lung cancer in non-smokers. The geographical homogeneity of the study reinforces the relevance of its findings but limits their scope. Further work on different populations and in different locations would help clarify the role of the ENT microbiota in the development of lung cancer and other respiratory diseases.

Summary
Off
Sidebar
On
Migrated content
Activé
Updated content
Désactivé
Old sources

 

 

Old content type
pro_article
Hide image
Off
News Pulmonology Otorhinolaryngology

Can the gut microbiota be used to better predict responses to IBD treatment?

Understanding, predicting treatment response, and tailoring therapy: a new study suggests that the gut microbiota of patients suffering from inflammatory bowel disease (IBD) could be used to predict the efficacy of an immunosuppressive treatment. This is a significant advance for diseases that are particularly debilitating. 

The gut microbiota IBD
IBD

Crohn’s disease and ulcerative colitis are both forms of IBD and have one thing in common: they cause uncontrolled inflammation of the lining of a section of the digestive tract, resulting in various symptoms during inflammatory flares. While there is currently no cure for these diseases, there are treatments such (sidenote: Infliximab A biotherapy that neutralizes TNF-α, the protein responsible for tissue inflammation. ) (IFX) aiming at reducing inflammation. However, a third of patients do not respond to this therapy and there is currently no (sidenote: Biomarker An objectively measured biological characteristic that makes it possible to evaluate responses to treatment. This response can be complete or partial. )  that predicts response to treatment. The researchers in this study may have found the answer in the gut microbiota.

Gut microbiota differs before treatment...

Numerous studies have shown a link between the composition of the gut microbiota (bacteria and, more recently, fungi) and IBD. Therefore, in order to identify markers that predict response to IFX therapy, the researchers evaluated the impact of IFX treatment on the gut microbiota composition (sidenote: 25 patients with Crohn’s disease (CD) and 47 with ulcerative colitis (UC). ) . Bacterial and fungal diversity in the gut microbiota was analyzed using fecal samples collected before treatment and 1 year after beginning of therapy. The patients were classified into three groups according to their response to treatment. The study revealed that the bacterial and fungal profiles of the three groups differed significantly before start of therapy.

...offering a predictive tool

Significant differences between the three groups of patients were also observed after initiation of treatment: non-responders had lower contents of anti-inflammatory bacteria and higher contents of pro-inflammatory bacteria and fungi (such as the genus Candida) compared with responders. These results suggest that the gut microbiota is involved in responses to treatment.

Based on these findings, the researchers subsequently identified certain bacteria and fungi present in the gut before start of treatment which could be used to predict responses to IFX therapy. Early identification of non-responders would permit rapid modification of treatment, limiting side effects and reducing the costs involved. A fully positive approach!

Summary
Off
Sidebar
Off
Migrated content
Activé
Updated content
Désactivé
Old sources

Sources:

Ventin-Holmberg R, Eberl A, Saqib S, et al. Bacterial and fungal profiles as markers of infliximab drug response in inflammatory bowel disease. J Crohns Colitis. 2020 Dec 10:jjaa252.

Old content type
article
Hide image
Off
News

Can dark chocolate protect against the effects of kidney disease?

Can a few squares of dark chocolate a day help fight complications in cases of chronic kidney disease (CKD)? Given the beneficial effects of cocoa on cardiovascular health, the microbiota and the brain, this may well be the case.

The gut microbiota What foods promote a balanced microbiota?

Theobroma cacao is the botanical name for the cacao tree; but did you know that Theobroma means “food of the gods” in Greek? Once reserved for priests and kings, chocolate has, fortunately, become more democratic. Today, it is consumed and appreciated throughout the world for its delicious taste and health benefits. With a cocoa content of more than 80%, dark chocolate is undoubtedly the most beneficial to health. For example, it contains specific compounds that could alleviate complications in chronic kidney disease (CKD).

Dark chocolate and gut microbiota: a winning combination?

The kidneys of patients with CKD have reduced functional capacity and no longer filter blood properly. This failure leads to an accumulation of molecules such as (sidenote: In total, more than 80 molecules are considered uremic toxins, among them hormones, peptides and even organic compounds. )  in the blood. These patients have an unbalanced gut microbiota (dysbiosis) that may contribute to the production of these toxins. Eating cocoa may modulate the gut microbiota by promoting the colonization by bacteria with known beneficial effects (Lactobacillus and Bifidobacterium) in the gut. A number of studies have also shown that, by modulating the gut microbiota, the ingestion of chocolate improves the integrity of the gut barrier, decreases inflammation and reduces uremic toxins.

Dark chocolate, the white knight of your cardiovascular system

Patients with CKD have a high risk of cardiovascular disease and premature death. Several studies have shown that the regular consumption of dark chocolate has a cardioprotective effect in healthy individuals. How so? By improving blood circulation, specifically, improving functioning of the blood vessels and reducing blood pressure. This improvement also leads to a reduced risk of stroke.

Munch on chocolate to boost your mood

We tend to forget that chronic illness often has a psychological impact on the patient. Beyond the simple pleasure of taste, the regular consumption of dark chocolate also stimulates the production of serotonin (a neurotransmitter involved in the regulation of behavior), which has an antidepressant effect. Although the consumption of dark chocolate (cocoa content of more than 80%) seems an interesting therapeutic alternative for patients with CKD, its potential impact on inflammation, cardiovascular risk and the gut microbiota has not yet been studied in a prospective clinical trial. But don’t let that stop you from treating yourself to a square of chocolate!

Recommended by our community

"Thank you for sharing that" - Suzanne Kohler

"Very good to know!!!! Thank you for this info!!!" - Melissa Beyer

"Thanks you for sharing this with me" - Donna Tatum

(From My health, my microbiota)

Summary
Off
Sidebar
On
Migrated content
Activé
Updated content
Désactivé
Old sources

Sources:

Fanton S, Cardozo LFMF, Combet E, Shiels PG, Stenvinkel P, Vieira IO, Narciso HR, Schmitz J, Mafra D. The sweet side of dark chocolate for chronic kidney disease patients. Clin Nutr. 2021 Jan;40(1):15-26.

Old content type
article
Hide image
Off
News

Antibiotic exposure during first six years of life disrupts gut microbiota and impairs child growth

A recent study has shown that exposure to antibiotics during the first six years of life disrupts the gut microbiota over the long term and impairs child growth.

The gut microbiota

Newborns subjected to antibiotic therapy reportedly exhibit an altered gut microbiota composition. However, the clinical or microbiological long-term consequences of this exposure remain unknown. Given the causal links between the intestinal microbiota and growth, obesity, and metabolic disease, researchers have suggested that neonatal antibiotic exposure might exert a long-lasting effect on childhood growth by disrupting the natural gut microbiota colonization process.

Altered development...

A study on 12,422 children born from singleton pregnancies at full term provided a host of information. The infants studied had no known growth abnormalities and did not require long-term prophylactic antibiotic treatment. 9.3% of the neonates in the study were exposed to (sidenote: Combination of intravenous benzylpenicillin and gentamicin for most infants )  within the first 14 days of life. Among exposed newborns, only boys had significantly lower weights compared to non-exposed children throughout the first six years of life. They also exhibited a significantly lower height and body mass index (BMI) between the ages of 2 and 6 years. This result was confirmed in a German cohort of 1,707 children followed from birth to 5 years. In contrast, antibiotic use after the neonatal period but during the first 6 years of life is associated with a significantly higher BMI in both boys and girls.

Antibiotics are an extraordinary scientific discovery that saves millions of lives but their excessive and inappropriate use has now raised serious concerns for health, notably with antibiotic resistance and microbiota dysbiosis. Let’s take a look at this dedicated page:

The ambivalent role of antibiotics

By destroying the bacteria responsible for infection, antibiotics can also lead…

...and a modified gut microbiota

To study the effect of neonatal antibiotic exposure on the gut microbiota, fecal samples were collected at the ages of 1, 6, 12, and 24 months from a separate group of 33 newborns, 13 of whom received intravenous benzylpenicillin and gentamicin within the first 48 hours of life. Twenty healthy newborns not exposed to antibiotics in the neonatal period were chosen as controls. The fecal microbiota was analyzed via 16S rRNA gene sequencing. Significant differences between the gut microbiota composition of the antibiotic-treated and control groups were observed after 1 and 6 months, demonstrating the persistence of the effect of antibiotic exposure on the microbiota. The genus Bifidobacterium was most substantially affected, with its content significantly reduced up to 24 months after antibiotic exposure.

What is the World AMR Awareness Week?

Each year, since 2015, the WHO organizes the World AMR Awareness Week (WAAW), which aims to increase awareness of global antimicrobial resistance.
Held on 18-24 November, this campaign encourages the general public, healthcare professionals and decision-makers to use antimicrobials carefully, to prevent the further emergence of antimicrobial resistance.

Gut dysbiosis in question?

To establish whether causal relationships exist between neonatal antibiotic exposure, gut dysbiosis and child growth, the researchers conducted a complementary study in (sidenote: Germ-free mice mice that have no microbes at all, raised in sterile conditions. ) . The mice received a fecal microbiota transplant (FMT) with feces obtained from antibiotic-exposed children 1 month and 2 years after the antibiotic treatment. A significant reduction in weight gain was observed in male mice that received FMT from antibiotic-exposed infants, as compared to male mice that received FMT from non-exposed infants. In contrast, growth in female mice was not affected.

These findings suggest a causal link between exposure to antibiotics during the first six years of life and growth disorders during childhood which could be caused by the gut dysbiosis that appears during the development of the gut microbiota.

Summary
Off
Sidebar
On
Migrated content
Activé
Updated content
Désactivé
Old content type
pro_article
Hide image
Off
News Pediatrics Gastroenterology

Depression: more accurate diagnosis thanks to the gut microbiota?

Two recent studies have opened up new avenues for the diagnosis and treatment of depressive disorders by analyzing the composition and metabolome of the gut microbiota.

The gut microbiota Geriatric depression: gut microbiota involved in remission? Depression: towards confirmation of a gut-brain dialogue? The Janus face of Antibiotics: Life Savers and Microbiota Disruptors
Actu PRO : Dépression : un diagnostic plus précis grâce au microbiote intestinal ?

In recent years, many studies have examined the link between gut dysbiosis and depression, a condition that affects more than 300 million people worldwide. Two new studies have confirmed the gut microbiota’s role in the disease.

The endocannabinoid system: the link between depression and the gut microbiota

In a study carried out by the Pasteur Institute, CNRS and INSERM, naive mice received a fecal microbiota transplant (FMT) from either healthy mice or mice with depression induced by unpredictable chronic mild stress (UCMS). The researchers then analyzed the gut microbiota, the metabolism of polyunsaturated fatty acids and neurogenesis in the hippocampus (a brain region heavily involved in the development of depressive symptoms). According to the study, the symptoms of the UCMS mice (reduced hippocampal neurogenesis, mood disorders) had been transferred to the FMT mice. Metabolomic analysis of the FMT mice revealed an altered fatty acid metabolism characterized by deficits in lipid precursors of endogenous cannabinoids. This resulted in impaired activity of the brain’s endocannabinoid system, which is thought to have induced depression. Increasing endogenous cannabinoids, either via the pharmacological blockade of the enzymes that degrade them or through diet, reduced depressive symptoms in the mice that received the FMT from the UCMS mice. This increase in endogenous cannabinoids also led to a recovery in neurogenesis in the hippocampus of these mice. Lastly, a gut microbiota dysbiosis characterized by a decrease in Lactobacilli abundance was observed in both the UCMS (donor) and FMT (recipient) mice. Complementing the dietary intake of the FMT mice with a strain of Lactobacilli was sufficient to increase both endogenous cannabinoid brain levels and hippocampal neurogenesis, thus alleviating mood disorders. This work in mice provides a new mechanistic scenario for the gut microbiota’s involvement in depression via the endogenous cannabinoid system. The study also suggests that dietary interventions or the use of probiotics may be an effective means to fight against the symptoms of this disease.

Gut biomarkers: towards more accurate diagnosis?

In a second study, Chinese and American researchers identified 3 bacteriophages, 47 bacterial species and 50 metabolites whose fecal abundance differed between a first cohort of 118 patients with untreated major depressive disorder (MDD) and 118 healthy controls (HC). The analysis of a second, validation cohort (38 treated MDD patients vs. 38 HC) showed that 6 biomarkers (2 bacteria, 2 phages and 2 metabolites) made it possible to discriminate between MDD patients and healthy controls in both cohorts with an accuracy of more than 90%. Lastly, the researchers showed that levels of fecal GABA and its relevant metabolites were consistently decreased in MDD patients relative to HC. These findings suggest that fecal GABA levels in the patients with MDD may be modulated by a panel of gut microbes, which in turn may be collectively implicated in the development of MDD. These findings provide new directions to uncover the pathogenesis of MDD. They also help improve MDD diagnosis, which is currently incomplete and subject to misdiagnosis, by focusing on the gut microbiota.

Recommended by our community

"The importance of the gut microbiota" - Comment translated from buzocaperuzo (From Biocodex Microbiota Institute on X)

"Congrats on finally getting this information out.." -@GloriaR56965767 (From Biocodex Microbiota Institute on X)

"Awesome!! " -@fmoral1959 (From Biocodex Microbiota Institute on X)

Summary
Off
Sidebar
On
Migrated content
Activé
Updated content
Désactivé
Old content type
pro_article
Hide image
Off
News Psychiatry Gastroenterology